MET Exon 14 Mutation

CI-VAR-00000995Explore in graph →CIViC 2778

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
MET Exon 14 Mutation	Crizotinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID7503 In a phase II trial patients with NSCLC harboring with MET amplification or MET exon 14 mutations were treated with multikinase inhibitor crizotinib. MET amplification was defined as MET/CEP7 ration >… (full text at CIViC) PMID 31416808 · Landi et al., 2019 · Open in CIViC	civic
MET Exon 14 Mutation	Crizotinib	Predictive	B	Supports Sensitivity Response	4	submitted	EID7840 In a phase 2 trial, patients with NSCLC harboring MET alterations were treated with crizotinib. MET alterations were kinase domain activating mutations included V1110L, H1112L, H1112Y, H1124D, M1149T,… (full text at CIViC) PMID 31932802 · Drilon et al., 2020 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.